- Home
- AIRT vs DTIL Comparison
AIRT vs DTIL Comparison
Compare AIRT & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- DTIL
- Stock Information
- Founded
- AIRT 1980
- DTIL 2006
- Country
- AIRT United States
- DTIL United States
- Employees
- AIRT N/A
- DTIL N/A
- Industry
- AIRT Air Freight/Delivery Services
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- AIRT Consumer Discretionary
- DTIL Health Care
- Exchange
- AIRT Nasdaq
- DTIL Nasdaq
- Market Cap
- AIRT 61.2M
- DTIL 55.3M
- IPO Year
- AIRT N/A
- DTIL 2019
- Fundamental
- Price
- AIRT $22.22
- DTIL $8.66
- Analyst Decision
- AIRT
- DTIL Strong Buy
- Analyst Count
- AIRT 0
- DTIL 2
- Target Price
- AIRT N/A
- DTIL $47.00
- AVG Volume (30 Days)
- AIRT 870.0
- DTIL 174.0K
- Earning Date
- AIRT 11-13-2025
- DTIL 11-07-2025
- Dividend Yield
- AIRT N/A
- DTIL N/A
- EPS Growth
- AIRT N/A
- DTIL N/A
- EPS
- AIRT N/A
- DTIL N/A
- Revenue
- AIRT $296,309,000.00
- DTIL $1,261,000.00
- Revenue This Year
- AIRT N/A
- DTIL N/A
- Revenue Next Year
- AIRT N/A
- DTIL $135.19
- P/E Ratio
- AIRT N/A
- DTIL N/A
- Revenue Growth
- AIRT 5.14
- DTIL N/A
- 52 Week Low
- AIRT $14.56
- DTIL $3.61
- 52 Week High
- AIRT $26.70
- DTIL $9.14
- Technical
- Relative Strength Index (RSI)
- AIRT 47.94
- DTIL 82.63
- Support Level
- AIRT $22.51
- DTIL $6.63
- Resistance Level
- AIRT $22.91
- DTIL $8.82
- Average True Range (ATR)
- AIRT 0.33
- DTIL 0.60
- MACD
- AIRT -0.04
- DTIL 0.19
- Stochastic Oscillator
- AIRT 35.14
- DTIL 94.82
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.